AstraZeneca taps the Cambridge wellspring
AstraZeneca plc has unveiled plans for the R&D center and global headquarters it will build in Cambridge, U.K.-the next major step in the pharma's strategy to improve pipeline productivity that it hopes will help it recover growth and regain ground in scientific leadership. The company expects that the new center will drive therapeutic innovation by allowing it to tap world-class research through partnerships with nearby institutes.
Last year, AstraZeneca announced plans to build the Cambridge headquarters-which would make it the first global pharma to establish a major research facility in the city. The new site is part of the pharma's larger goal to concentrate its small molecule and biologics R&D in three places by 2016-with the Cambridge headquarters joining two existing sites in Gaithersburg, Md., and Mölndal, Sweden...